BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38282149)

  • 1. Single-cell RNA sequencing reveals the mechanism of PI3K/AKT/mTOR signaling pathway activation in lung adenocarcinoma by KRAS mutation.
    Xu L; Ding R; Song S; Liu J; Li J; Ju X; Ju B
    J Gene Med; 2024 Jan; 26(1):e3658. PubMed ID: 38282149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis-generating study.
    Huang L; Yang H; Chen K; Yuan J; Li J; Dai G; Gu M; Shi Y
    Clin Transl Med; 2023 Dec; 13(12):e1500. PubMed ID: 38037549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synaptotagmin 12 (SYT12) Gene Expression Promotes Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
    Liu K; Luo J; Shao C; Ren Z; Sun S; Zhu Y; Zhou H; Jiang Z; Li X; Gu W; Xu Y; Qiang Y; Ren B; Xu L; Wu H; Shen Y
    Med Sci Monit; 2020 Feb; 26():e920351. PubMed ID: 32108133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of PI3K-Akt/mTOR/AMPK signaling pathway genetic mutation with efficacy and prognosis in nasopharyngeal carcinoma.
    Chen Y; He Q; Ma H; Zhang L; Liu F; Han Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Feb; 47(2):165-173. PubMed ID: 35545406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.
    Dogan Turacli I; Ozkan AC; Ekmekci A
    Tumour Biol; 2015 Dec; 36(12):9339-45. PubMed ID: 26108998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS gene silencing inhibits the activation of PI3K-Akt-mTOR signaling pathway to regulate breast cancer cell epithelial-mesenchymal transition, proliferation and apoptosis.
    Zhang Y; Liu JL; Wang J
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3085-3096. PubMed ID: 32271426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PIK3CA regulates development of diabetes retinopathy through the PI3K/Akt/mTOR pathway.
    Guan R; Kang Z; Li L; Yan X; Gao T
    PLoS One; 2024; 19(1):e0295813. PubMed ID: 38194422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UHMK1 promotes lung adenocarcinoma oncogenesis by regulating the PI3K/AKT/mTOR signaling pathway.
    Li Y; Wang S; Jin K; Jin W; Si L; Zhang H; Tian H
    Thorac Cancer; 2023 Apr; 14(12):1077-1088. PubMed ID: 36919755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyanidin-3-glucoside suppresses the progression of lung adenocarcinoma by downregulating TP53I3 and inhibiting PI3K/AKT/mTOR pathway.
    Chen X; Zhang W; Xu X
    World J Surg Oncol; 2021 Aug; 19(1):232. PubMed ID: 34362378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
    PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in
    da Silva-Oliveira RJ; Gomes INF; da Silva LS; Lengert AVH; Laus AC; Melendez ME; Munari CC; Cury FP; Longato GB; Reis RM
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TM6SF1 suppresses the progression of lung adenocarcinoma and M2 macrophage polarization by inactivating the PI3K/AKT/mtor pathway.
    Huang S; Zhao H; Lou X; Chen D; Shi C; Ren Z
    Biochem Biophys Res Commun; 2024 Jul; 718():149983. PubMed ID: 38718735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
    Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Junctional adhesion molecule-like protein as a novel target for kaempferol to ameliorate lung adenocarcinoma.
    Wu Q; Wang YB; Che XW; Wang H; Wang W
    J Integr Med; 2023 May; 21(3):268-276. PubMed ID: 37069006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
    Ganesan P; Janku F; Naing A; Hong DS; Tsimberidou AM; Falchook GS; Wheler JJ; Piha-Paul SA; Fu S; Stepanek VM; Lee JJ; Luthra R; Overman MJ; Kopetz ES; Wolff RA; Kurzrock R
    Mol Cancer Ther; 2013 Dec; 12(12):2857-63. PubMed ID: 24092809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma.
    Makinoshima H; Takita M; Saruwatari K; Umemura S; Obata Y; Ishii G; Matsumoto S; Sugiyama E; Ochiai A; Abe R; Goto K; Esumi H; Tsuchihara K
    J Biol Chem; 2015 Jul; 290(28):17495-504. PubMed ID: 26023239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SLITRK6 promotes the progression of lung adenocarcinoma by regulating PI3K/AKT/mTOR signaling and Warburg effect.
    Yu F; Zhao X; Li M; Meng M
    Apoptosis; 2023 Aug; 28(7-8):1216-1225. PubMed ID: 37219677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.
    Janku F; Tsimberidou AM; Garrido-Laguna I; Wang X; Luthra R; Hong DS; Naing A; Falchook GS; Moroney JW; Piha-Paul SA; Wheler JJ; Moulder SL; Fu S; Kurzrock R
    Mol Cancer Ther; 2011 Mar; 10(3):558-65. PubMed ID: 21216929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.